Patents by Inventor Emily Stanley

Emily Stanley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Autotaxin inhibitors
    Patent number: 9630945
    Abstract: The present invention relates to novel compounds of formula (I) (I) that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: April 25, 2017
    Assignee: Novartis AG
    Inventors: Vikki Furminger, Owen Rhys Hughes, Darren Mark Le Grand, Emily Stanley, Christopher Thomson
  • Autotaxin inhibitors
    Publication number: 20170007614
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Application
    Filed: July 14, 2016
    Publication date: January 12, 2017
    Applicant: NOVARTIS AG
    Inventors: Darren Mark Legrand, Vikki Furminger, Christopher Thomson, Owen Rhys Hughes, Emily Stanley
  • Autotaxin inhibitors
    Patent number: 9409895
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 9, 2016
    Assignee: Novartis AG
    Inventors: Darren Mark Legrand, Vikki Furminger, Christopher Thomson, Owen Rhys Hughes, Emily Stanley
  • Autotaxin inhibitors
    Publication number: 20150307475
    Abstract: The present invention relates to novel compounds of formula (I) (I) that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition.
    Type: Application
    Filed: December 17, 2013
    Publication date: October 29, 2015
    Applicant: NOVARTIS AG
    Inventors: Vikkie Furminger, Owen Rhys Hughes, Darren Mark Legrand, Emily Stanley, Christopher Thomson
  • Autotaxin inhibitors
    Publication number: 20140171403
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 19, 2014
    Applicant: Novartis AG
    Inventors: Darren Mark Legrand, Vikki Furminger, Christopher Thomson, Owen Rhys Hughes, Emily Stanley
  • Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists
    Publication number: 20140088105
    Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
    Type: Application
    Filed: November 22, 2013
    Publication date: March 27, 2014
    Applicant: NOVARTIS AG
    Inventors: David Beattie, Andrew James Culshaw, Lisa Rooney, Emily Stanley
  • Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists
    Patent number: 8614213
    Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing (CRF1) receptor antagonists.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventors: David Beattie, Andrew James Culshaw, Lisa Rooney, Emily Stanley
  • Organic compounds 75074
    Patent number: 8318935
    Abstract: A compound of formula (I), or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M2, L1, L2, W1, W2, X1, X2, Y1, Y2, A, R5 and R5a are as defined herein for the for treatment of conditions treatable by the blockade of an epithelial sodium channel, particularly conditions benefiting from mucosal hydration.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: November 27, 2012
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, Rebecca Butler, Paul Oakley, Stephen Paul Collingwood, Nichola Smith, Emily Stanley, Maria Ines Rodriguez Perez
  • Organic compounds
    Patent number: 8273900
    Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: September 25, 2012
    Assignee: Novartis AG
    Inventors: David Beattie, Anny-Odile Colson, Andrew James Culshaw, Lisa Sharp, Emily Stanley, Lilya Sviridenko
  • Organic compounds
    Publication number: 20110152261
    Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing (CRF1) receptor antagonists.
    Type: Application
    Filed: August 5, 2009
    Publication date: June 23, 2011
    Inventors: David Beattie, Anny-Odile Colson, Andrew James Culshaw, Lisa Rooney, Emily Stanley, Lilya Sviridenko
  • ORGANIC COMPOUNDS75074
    Publication number: 20100105660
    Abstract: A compound of formula (I), or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M2, L1, L2, W1, W2, X1, X2, Y1, Y2, A, R5 and R5a are as defined herein for the for treatment of conditions treatable by the blockade of an epithelial sodium channel, particularly conditions benefiting from mucosal hydration.
    Type: Application
    Filed: May 5, 2008
    Publication date: April 29, 2010
    Inventors: Robin Alec Fairhurst, Rebecca Fraser, Paul Oakley, Stephen Paul Collingwood, Nichola Smith, Emily Stanley, Maria Ines Rodriguez Perez
  • Organic compounds
    Publication number: 20100035898
    Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
    Type: Application
    Filed: July 31, 2009
    Publication date: February 11, 2010
    Inventors: David Beattie, Anny-Odile Colson, Andrew James Culshaw, Lisa Sharp, Emily Stanley, Lilya Sviridenko